Date: 2011-01-17
Type of information: Licensing agreement
Compound: polyethylenimine (PEI) for in vitro transfection applications for research purposes
Company: Polyplus-transfection (France)Roche Glycart (Switzerland)
Therapeutic area:
Type agreement: Licensing
Action mechanism:
Disease:
Details: Polyplus-transfection has granted Roche Glycart AG, a non exclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes. By entering into this license agreement, Roche Glycart AG becomes one of Polyplus’ sub-licensees for the use of PEI-mediated transfection applications for research purposes. This license will enable Roche Glycart AG to use this transfection reagent in its research to produce antibody-based products.
Financial terms: Financial terms were not disclosed.
Latest news:
